{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:00:10Z","timestamp":1787065210681,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd011748","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000}}],"reference-count":111,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011748.pub2","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T12:44:23Z","timestamp":1493383463000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease"],"prefix":"10.1002","author":[{"given":"Amand F","family":"Schmidt","sequence":"first","affiliation":[{"name":"University College London; Institute of Cardiovascular Science; 222 Euston Road, Room 206 London UK NW1 2DA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy S","family":"Pearce","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine; Department of Non-communicable Disease Epidemiology; Keppel Street London UK WC1 E7HT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T","family":"Wilkins","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine; The Department of Medicine (Cardiology) and the Department of Preventive Medicine; Suite 1400 680 N. Lakeshore Drive Chicago Illinois USA 60611"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Overington","sequence":"additional","affiliation":[{"name":"Medicines Discovery Catapult; 40 Churchway Alderly Edge UK SK10 4TG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroon D","family":"Hingorani","sequence":"additional","affiliation":[{"name":"University College London; Institute of Cardiovascular Science; 222 Euston Road, Room 206 London UK NW1 2DA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P","family":"Casas","sequence":"additional","affiliation":[{"name":"University College London; Farr Institute of Health Informatics Research; 222 Euston Road London UK NW1 2DA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,28]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD011748.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","article-title":"Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia","volume":"115","author":"Ballantyne","year":"2015","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0003|cit3","unstructured":"Tingley W Mosesova S Baruch A Davis JD Budha N Vilimovskij A Effects of RG7652, a monoclonal antibody against proprotein convertase Subtilisin\/Kexin type 9, on LDL cholesterol in patients with coronary heart disease or high risk: results from the EQUATOR study European Heart Journal 2014 371"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0004|cit4","first-page":"1","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"online","author":"Sabatine","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011748.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0006|cit6","unstructured":"Stroes E Guyton JR Farnier M Rader D Moriarty PM Bergeron J Efficacy and safety of 150 mg and 300 mg every 3 weeks in patients with poorly controlled hypercholesterolemia: the ODYSSEY CHOICE I and CHOICE II studies Journal of the American College of Cardiology 2015 Exhibit 99.1"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0007|cit7","unstructured":"Stroes E Guyton JR Farnier M Rader D Moriarty PM Bergeron J Efficacy and safety of 150 mg and 300 mg every 3 weeks in patients with poorly controlled hypercholesterolemia: the ODYSSEY CHOICE I and CHOICE II studies Journal of the American College of Cardiology 2015 Exhibit 99.1"},{"issue":"6","key":"10.1002\/14651858.CD011748.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"American Heart Journal"},{"issue":"19","key":"10.1002\/14651858.CD011748.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"European Heart Journal"},{"issue":"43","key":"10.1002\/14651858.CD011748.pub2-BIB0010|cit10","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"European Heart Journal"},{"issue":"43","key":"10.1002\/14651858.CD011748.pub2-BIB0011|cit11","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0012|cit12","unstructured":"Ginsberg HN Rader DJ Raal F Guyton JR Lorenzato C Pordy R ODYSSEY HIGH FH: Efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia Conference abstract Published online 2014"},{"issue":"16","key":"10.1002\/14651858.CD011748.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"International Journal of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD011748.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerorsis"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"issue":"16","key":"10.1002\/14651858.CD011748.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0019|cit19","first-page":"1","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"online","author":"Ridker","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0020|cit20","unstructured":"Baruch A Peng K Leabman M Budha N Luca D Cowan KJ Effect of RG7652, a mAb against PCSK9, on apolipoprotein B, oxidized LDL, lipoprotein(A) and lipoprotein-associated phospholipase a2 in healthy individuals with elevated LDL-C Circulation 2013"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Cho L Rocco M Colquhoun D Sullivan D Rosenson RS Dent R Clinical profile of statin intolerance in the phase 3 gauss-2 study Canadian Journal of Cardiology 2014 S79","DOI":"10.1016\/j.cjca.2014.07.068"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jacc.2013.09.048","article-title":"AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of National Cholesterol Education Program-Adult Treatment Panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57)","volume":"63","author":"Desai","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins","volume":"60","author":"Dias","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0024|cit24","unstructured":"Dufour R Moriarty PM Genestin E Sasiela WJ Du Y Ferrand AC Effect of REGN727\/SAR236553 anti-proprotein convertase subtilisin\/kexin type 9 fully human monoclonal antibody in patients with elevated triglycerides\/low high-density lipoprotein cholesterol: data from three phase 2 studies (NCT:01266876; 01288469; 01288443) Circulation 2012"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0025|cit25","unstructured":"Gaudet D Kereiakes D McKenney J Roth E Hanotin C Gipe D Effect of SAR236553\/REGN727 fully human monoclonal anti-proprotein convertase subtilisin\/kexin type 9 antibody on plasma lipoprotein(a) concentrations: pooled analysis from three phase 2 studies (NCT:01266876; 01288469; 01288443) Circulation 2012"},{"issue":"3","key":"10.1002\/14651858.CD011748.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jacl.2013.03.091","article-title":"Alirocumab, a fully human monoclonal antibody to PCSK9, reduces high plasma lp(a) concentration: pooled analysis of 352 patients from phase 2","volume":"7","author":"Gaudet","year":"2013","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0027|cit27","unstructured":"Gumbiner B Udata C Joh T Liang H Wan H Shelton D The effects of multiple dose administration of RN316 (PF-04950619), a humanized IgG2a monoclonal antibody binding proprotein convertase snbtilisin kexin type 9, in hypercholesterolemic subjects Circulation 2012"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0028|cit28","unstructured":"Hopkins PN Swergold GD Mellis S Bruckert E Luc G Mendoza J A randomized placebo-phase clinical trial with the monoclonal antibody alirocumab demonstrates reductions in low-density lipoprotein cholesterol in patients with proprotein convertase subtilisin\/kexin type 9 gain-of-function mutations Circulation 2013"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Jones PH Bays H Chaudhari U Pordy R Lorenzato C Miller K Pooled safety and adverse events in nine randomized, placebo-controlled, phase 2 and 3 clinical trials of alirocumab Journal of the American College of Cardiology 2015 A1363","DOI":"10.1016\/S0735-1097(15)61363-8"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Kastelein J Nissen S Rader D Krueger K Wang MD Safety and efficacy of LY 3015014, a new monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 (PCSK 9) with an inherently longer duration of action, in patients with primary hypercholesterolemia: a randomized, placebo-controlled, dose-ranging, phase 2 study Journal of the American College of Cardiology 2015 A1591","DOI":"10.1016\/S0735-1097(15)61591-1"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.amjcard.2011.09.019","article-title":"Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia","volume":"109","author":"Kawashiri","year":"2012","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD011748.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nrendo.2014.205","article-title":"Therapy: PCSK9 inhibitors for treating familial hypercholesterolaemia","volume":"11","author":"Mabuchi","year":"2015","journal-title":"Nature Reviews Endocrinology"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/CIRCRESAHA.112.275859","article-title":"Antibodies to PCSK9: a superior way to lower LDL cholesterol?","volume":"111","author":"Maxwell","year":"2012","journal-title":"Circulation Research"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrcardio.2013.201","article-title":"Dyslipidaemia: 1-year results from OSLER trial of anti-PCSK9 monoclonal antibody evolocumab","volume":"11","author":"Mearns","year":"2014","journal-title":"Nature Reviews Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD011748.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jacl.2013.03.084","article-title":"Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin\/kexin type 9: therapeutic dosing in phase 3 studies","volume":"7","author":"Pordy","year":"2013","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0036|cit36","doi-asserted-by":"crossref","unstructured":"Raal F Nelson P Langslet G Basart DCG Civeira F Lopez-Miranda J Safety, tolerability, and efficacy of long-term administration of monthly AMG 145 in subjects with heterozygous familial hypercholesterolemia Global Heart 2014 e139","DOI":"10.1016\/j.gheart.2014.03.1724"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0037|cit37","unstructured":"Raal F Giugliano RP Sabatine MS Koren MJ Blom D Honarpour N Long-term reduction in lipoprotein(A) with the PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of 3278 patients in phase 2, 3, and open label extension studies Circulation 2014"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Shaywitz AJ Dias C Smith B Gao B Gibbs J Emery M AMG 145, a fully human monoclonal antibody against PCSK9, reduces LDL-C in healthy volunteers and patients on stable doses of statins+ Journal of Clinical Lipidology 2012 286 7","DOI":"10.1016\/j.jacl.2012.04.066"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MCA.0000000000000113","article-title":"Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia","volume":"25","author":"Stawowy","year":"2014","journal-title":"Coronary Artery Disease"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0041|cit41","unstructured":"Stein EA Somaratne R Schou MB Civeira F Sullivan D Watts GF Efficacy and tolerability of long-term treatment with AMG 145 in patients with statin intolerance Circulation 2013"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0042|cit42","first-page":"2","article-title":"Safety, lipid, and lipoprotein effects of REGN727\/SAR236553, a fully-human proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody administered intravenously to healthy volunteers","volume":"122","author":"Swergold","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0043|cit43","unstructured":"Swergold G Smith W Mellis S Logan D Webb C Wu R Inhibition of proprotein convertase subtilisin\/kexin type 9 with a monoclonal antibody REGN727\/SAR236553, effectively reduces low-density-lipoprotein cholesterol, as mono or add-on therapy in heterozygous familial and non familial hypercholesterolemia Circulation 2011 2"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Wan H Gumbiner B Joh T Udata C Forgues P Garzone PD Effects of RN316 (pf-04950615), a humanized igg2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, on lipoprotein particles in hypercholesterolemic subjects Journal of the American College of Cardiology 2013 E1387","DOI":"10.1016\/S0735-1097(13)61387-X"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0045|cit45","first-page":"1","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"online first","author":"Ridker","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0046|cit46","unstructured":"NCT02729025 Effects of Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)). (ANITSCHKOW) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02729025 (first received: March 8, 2016)"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0047|cit47","unstructured":"NCT02207634 Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02207634 (first received July 31, 2014)"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0048|cit48","unstructured":"NCT02392559 Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders (HAUSER-RCT) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02392559 (first received February 25, 2015)"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0049|cit49","unstructured":"NCT02833844 Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia\/Mixed Dyslipidemia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02833844 (first received June 13, 2016)"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0050|cit50","unstructured":"NCT02642159 Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02642159 (first received December 24, 2015)"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0051|cit51","unstructured":"NCT01663402 ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01663402 (first received August 8, 2012)"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0052|cit52","unstructured":"NCT01624142 Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01624142 (first received June 5, 2012)"},{"issue":"2","key":"10.1002\/14651858.CD011748.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2013","journal-title":"Nature Genetics"},{"issue":"7382","key":"10.1002\/14651858.CD011748.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"issue":"22","key":"10.1002\/14651858.CD011748.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","article-title":"PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses","volume":"55","author":"Benn","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD011748.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD011748.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Statistics in Medicine"},{"issue":"25","key":"10.1002\/14651858.CD011748.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0059|cit59","unstructured":"Capewell S Allender S Critchley J Lloyd-Williams F O'Flaherty M Rayner M Modelling the UK burden of cardiovascular disease to 2020: a research report for the Cardio & Vascular Coalition and the British Heart Foundation. British Heart Foundation, 2008 http:\/\/www.healthimpact.org.uk\/Home\/Links"},{"issue":"1","key":"10.1002\/14651858.CD011748.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0061|cit61","first-page":"1","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"Ahead of print","author":"Catapano","year":"2016","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD011748.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCGENETICS.111.961144","article-title":"Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial","volume":"5","author":"Chasman","year":"2012","journal-title":"Circulation. Cardiovascular Genetics."},{"issue":"2","key":"10.1002\/14651858.CD011748.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nature Genetics"},{"issue":"12","key":"10.1002\/14651858.CD011748.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0065|cit65","first-page":"1","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"Ahead of print","author":"Collins","year":"2016","journal-title":"Lancet"},{"issue":"9493","key":"10.1002\/14651858.CD011748.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Cholesterol Treatment Trialists' (CTT) Collaborators","year":"2005","journal-title":"Lancet"},{"issue":"9976","key":"10.1002\/14651858.CD011748.pub2-BIB0067|cit67","first-page":"1397","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174\u2008000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2005","journal-title":"Lancet"},{"issue":"9841","key":"10.1002\/14651858.CD011748.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011748.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.acvd.2013.10.007","article-title":"PCSK9: From discovery to therapeutic applications","volume":"107","author":"Farnier","year":"2014","journal-title":"Archives of Cardiovascular Disease"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0070|cit70","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research Briefing document Praluent (alirocumab) injection The Endocrinologic and Metabolic Drugs Advisory Committee Meeting"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"22","author":"Ference","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"5520","key":"10.1002\/14651858.CD011748.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1126\/science.1060458","article-title":"Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein","volume":"292","author":"Garcia","year":"2001","journal-title":"Science"},{"issue":"1","key":"10.1002\/14651858.CD011748.pub2-BIB0073|cit73","first-page":"1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"GRADE Working Group","year":"2004","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD011748.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0075|cit75","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1073\/pnas.84.19.6919","article-title":"Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding","volume":"84","author":"Innerarity","year":"1987","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"6","key":"10.1002\/14651858.CD011748.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ahj.2014.09.001","article-title":"Reducing the burden of disease and death from familial hypercholesterolemia: a call to action","volume":"168","author":"Knowles","year":"2014","journal-title":"American Heart Journal"},{"issue":"Suppl C","key":"10.1002\/14651858.CD011748.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"8C","DOI":"10.1016\/S0828-282X(10)71075-8","article-title":"The impact of social determinants on cardiovascular disease","volume":"26","author":"Kreatsoulas","year":"2010","journal-title":"Canadian Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD011748.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/S2214-109X(13)70089-5","article-title":"Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010","volume":"1","author":"Krishnamurthi","year":"2013","journal-title":"Lancet Global Health"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0080|cit80","article-title":"Chapter 6: Searching for studies","volume-title":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Lefebvre","year":"2011. www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD011748.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","author":"Lipinsky","year":"2016","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2016.14568","article-title":"Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes","volume":"13","author":"Lotta","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD011748.pub2-BIB0083|cit83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD011748.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1755-5922.12093","article-title":"A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects","volume":"32","author":"Lunven","year":"2014","journal-title":"Cardiovascascular Therapy"},{"issue":"5","key":"10.1002\/14651858.CD011748.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cjca.2011.05.007","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2011","journal-title":"Canadian Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD011748.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"issue":"14","key":"10.1002\/14651858.CD011748.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1161\/CIRCULATIONAHA.113.004046","article-title":"The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study","volume":"129","author":"Moran","year":"2014","journal-title":"Circulation"},{"issue":"9859","key":"10.1002\/14651858.CD011748.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0089|cit89","doi-asserted-by":"crossref","unstructured":"Navarese EP Ko\u0142odziejczak M Schulze V Gurbel PA Tantry U Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis Annals of Internal Medicine 2015 40 51 10.7326\/M14-2957","DOI":"10.7326\/M14-2957"},{"issue":"1","key":"10.1002\/14651858.CD011748.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/eb-2013-101340","article-title":"Implementing GRADE: calculating the risk difference from the baseline risk and the relative risk","volume":"19","author":"Newcombe","year":"2014","journal-title":"Evidence-Based Medicine"},{"issue":"15","key":"10.1002\/14651858.CD011748.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"45","key":"10.1002\/14651858.CD011748.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosedand undertreated in the general population:guidance for clinicians to prevent coronary heart disease","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0093|cit93","unstructured":"Pfizer Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor http:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor (accessed 24 April 2017)"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0094|cit94","unstructured":"R Development Core Team R: A language and environment for statistical computing 2014"},{"issue":"4","key":"10.1002\/14651858.CD011748.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","article-title":"Heart disease and stroke statistics - 2011 update: a report from the American Heart Association","volume":"123","author":"Roger","year":"2011","journal-title":"Circulation"},{"issue":"16","key":"10.1002\/14651858.CD011748.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"9716","key":"10.1002\/14651858.CD011748.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD011748.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/sim.5929","article-title":"Comments on 'the use of propensity scores and observational data to estimate randomized controlled trial generalizability bias' by Taylor R. Pressler and Eloise E. Kaizar, Statistics in Medicine 2013","volume":"33","author":"Schmidt","year":"2014","journal-title":"Statistics in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011748.pub2-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011748","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","author":"Schmidt","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011748.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pds.3965","article-title":"Tailoring treatments using treatment effect modification","volume":"25","author":"Schmidt","year":"2016","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD011748.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4701","key":"10.1002\/14651858.CD011748.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.2988123","article-title":"The LDL receptor gene: a mosaic of exons shared with different proteins","volume":"228","author":"Sudhof","year":"1985","journal-title":"Science"},{"issue":"1","key":"10.1002\/14651858.CD011748.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Statistics in Medicine"},{"issue":"9965","key":"10.1002\/14651858.CD011748.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2014","journal-title":"Lancet"},{"issue":"20","key":"10.1002\/14651858.CD011748.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V","article-title":"Explaining heterogeneity in meta-analysis: a comparison of methods","volume":"18","author":"Thompson","year":"1999","journal-title":"Statistics in Medicine"},{"issue":"11","key":"10.1002\/14651858.CD011748.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7321","key":"10.1002\/14651858.CD011748.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/bmj.323.7321.1123","article-title":"Statistics notes: analysing controlled trials with baseline and follow up measurements","volume":"323","author":"Vickers","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011748.pub2-BIB0109|cit109","unstructured":"World Health Organization The global burden of disease: 2004 update http:\/\/www.who.int\/healthinfo\/global_burden_disease\/2004_report_update\/en\/"},{"issue":"11","key":"10.1002\/14651858.CD011748.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nature Genetics"},{"issue":"123","key":"10.1002\/14651858.CD011748.pub2-BIB0111|cit111","first-page":"1","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Medicine"}],"updated-by":[{"DOI":"10.1002\/14651858.cd011748.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD011748.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:59:18Z","timestamp":1628549958000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD011748.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Heart Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,4,28]]},"references-count":111,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011748.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD011748.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,28]]}}}